NASDAQ$XERS
Xeris Biopharma Holdings Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported financial results for Q3 2021 and recent highlights, including the completion of the Strongbridge Biopharma plc acquisition.
Xeris Biopharma reported strong growth in Q3 2021, with pro forma net sales of $22.5 million driven by Gvoke and Keveyis. The company completed the Strongbridge acquisition and is on track to realize $50 million in synergies. They anticipate year-end cash, cash equivalents, and investments of approximately $100 million.
- Completed the acquisition of Strongbridge Biopharma.
- Q3 pro forma net sales of $22.5M: Gvoke® and Keveyis® $11.0M and $11.5M, respectively
- Gvoke and Keveyis net sales grew 19% compared to Q2 2021 and combined are on track to achieve $76M to $80M full year 2021 net sales
- On track to realize $50M in synergies; anticipates year-end cash, cash equivalents, and investments of approximately $100M
Headline financials
Revenue & EPS history
Xeris Biopharma · Revenue · Quarterly
$11M
Revenue by segment
Xeris Biopharma · $22.5M total across 2 segments · Q3 2021
- Keveyis$11.5M—51.1%
- Gvoke$11M—48.9%
Forward guidance
The company is preparing for the potential commercial launch of Recorlev in Q1 2022 and expects its cash resources to be sufficient to sustain operations through at least the end of 2022.
Tailwinds
- Continued strong demand for both Gvoke and Keveyis.
- Completed integration of the Strongbridge acquisition.
- On track to realize $50 million in synergies.
- Strong cash position to drive continued growth of Gvoke and Keveyis.
- Achieved a full 12-month interest-only extension on our debt facility.
Headwinds
- Incurred approximately $40 million in acquisition-related one-time costs and debt extinguishment.
- Net loss of $26.0 million for the quarter.
- Total operating expenses of $32.198 million for the quarter.
- R&D expenses of $5.663 million for the quarter.
- SG&A expenses of $26.535 million for the quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-0.8%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+4.5%
Avg return
30 days after
40%
12 / 30 earnings
Positive
+33.5%
Q1 2020
Best reaction
-21.8%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.1% | -1.9% | -3.1% | |
| Q4 2025 | -2.0% | -5.1% | -1.3% | |
| Q3 2025 | -21.8% | -24.6% | -34.0% | |
| Q1 2025 | +15.2% | +9.4% | +2.2% | |
| Q4 2024 | +9.5% | +16.4% | +17.0% | |
| Q3 2024 | -2.4% | -6.2% | +9.2% | |
| Q2 2024 | +8.9% | +19.2% | +17.8% | |
| Q1 2024 | -4.9% | +2.7% | +25.9% | |
| Q4 2023 | -20.8% | -26.9% | -33.8% | |
| Q3 2023 | -14.9% | -21.2% | +2.5% | |
| Q2 2023 | -5.6% | -8.4% | -14.1% | |
| Q1 2023 | +22.1% | +20.8% | +22.9% | |
| Q4 2022 | -18.3% | -20.9% | +23.5% | |
| Q3 2022 | +0.0% | -5.3% | -3.3% | |
| Q2 2022 | +7.1% | +11.2% | +7.1% | |
| Q1 2022 | -15.1% | +23.5% | +5.6% | |
| Q4 2021 | +9.3% | +8.1% | -4.5% | |
| Q3 2021 | +6.1% | +26.5% | +13.3% | |
| Q2 2021 | -18.9% | -18.9% | -4.6% | |
| Q1 2021 | +3.3% | +7.8% | +18.6% | |
| Q4 2020 | -8.1% | +1.9% | -9.7% | |
| Q3 2020 | -0.9% | -3.1% | -26.1% | |
| Q2 2020 | -1.8% | +25.1% | +43.6% | |
| Q1 2020 | +33.5% | +62.8% | +100.0% | |
| Q4 2019 | -10.9% | -21.9% | -2.5% | |
| Q3 2019 | -10.1% | -8.2% | -1.9% | |
| Q2 2019 | -1.4% | +5.9% | +5.9% | |
| Q1 2019 | +13.3% | +13.3% | -22.8% | |
| Q4 2018 | -5.8% | -10.4% | -6.2% | |
| Q3 2018 | +5.8% | -9.3% | -13.0% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro